ZYUS Life Sciences Completes Phase 2a UTOPIA-1 Trial for Novel Non-Opioid Cancer Pain Treatment
核心洞察
ZYUS Life Sciences has completed the final study visit for the last patient in its Phase 2a UTOPIA-1 trial evaluating Trichomylin® softgel capsules for moderate to severe cancer-related pain.
The single-arm, proof-of-concept study investigated the safety and preliminary analgesic efficacy of the cannabinoid-based drug candidate in patients with advanced cancer.
Top-line results are expected in Q2 2026, building on encouraging preliminary data that suggested the treatment was effective, safe, well-tolerated, and showed potential for opioid-sparing effects.
ZYUS Life Sciences Corporation (搜索) announced the completion of the final study visit by the last patient in its Phase 2a UTOPIA-1 trial, marking a significant milestone in the development of Trichomylin® softgel capsules as a novel non-opioid treatment for cancer-related pain. The clinical-stage life sciences company expects to report top-line results in Q2 2026.
Trial Design and Patient Population
The UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe cancer-related pain. The study has reached the last patient last visit milestone, completing patient participation in this Phase 2a evaluation.
Clinical Significance and Unmet Medical Need
"Cancer-related pain remains a complex condition to manage, and there remains a need for alternative treatment approaches," said Dr. Julie Stakiw, Chief Medical Officer of ZYUS. The completion of patient participation represents progress toward addressing this significant unmet medical need in oncology care.
Preliminary Efficacy Signals
The upcoming results will build on encouraging preliminary data previously announced by the company. According to ZYUS, the preliminary findings suggested that Trichomylin® softgel capsules was effective for pain management, safe and well tolerated, and indicated potential for opioid-sparing effects in the study population.
Company Leadership Perspective
"The completion of the last patient visit represents a key milestone for the UTOPIA-1 trial, and we look forward to analyzing the full dataset, including preliminary data observed to date, to inform the continued drug development of Trichomylin® softgel capsules," said Brent Zettl, President and CEO of ZYUS. "This milestone reflects our ongoing commitment to advancing potential non-opioid treatment options for patients with cancer-related pain."
Cannabinoid-Based Drug Development
ZYUS Life Sciences focuses on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. The company aims to secure intellectual property protection for its innovative therapies while pursuing regulatory approval of non-opioid-based pharmaceutical solutions.
Next Steps and Timeline
Top-line results from the Phase 2a UTOPIA-1 trial are expected to be reported in Q2 2026, following completion of data cleaning and analysis. The trial is registered on clinicaltrials.gov with the identifier NCT06533657. These findings will inform the continued drug development of Trichomylin® softgel capsules and potential progression to later-stage clinical trials.